Objective To evaluate the long-term efficacy of interleukin (IL)-17A inhibition with secukinumab on structural bone changes and clinical outcomes in psoriatic arthritis (PsA). Methods We conducted a ...
Background Rheumatoid arthritis (RA) is associated with inflammation-driven hypercoagulability and increased venous ...
Background Systemic lupus erythematosus (SLE) predominantly affects women of childbearing age and is often associated with ...
Objectives The intrauterine environment may influence childhood immune-mediated disease risk. We investigated whether ...
It is postulated that fibromyalgia reflects a neurobiologically rooted imbalance between overactivated threat systems and ...
Background Approximately 10%–20% of patients with Kawasaki disease (KD) are resistant to intravenous immunoglobulins (IVIG) ...
Objective To test whether ultrasonography of patients with rheumatoid arthritis (RA) in the American College of ...
Introduction Evidence of treat-to-target strategies including secukinumab dose escalation in patients with axial spondyloarthritis (axSpA) remains limited. We investigated the effect of a ...
Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). Methods We analysed data from the ...
Cost-effectiveness planes to visually show the differences in societal costs (y-axis) and effects (x-axis) between treatment and placebo. On top, results from the total trial population (n=236) are ...
Introduction An important consideration in the treatment of patients with psoriatic arthritis (PsA) is whether the addition of methotrexate (MTX) to biologics has greater efficacy than biologic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results